background
although
amoxicillinclavulan
recommend
firstlin
empir
oral
antibiot
treatment
nonsever
exacerb
children
bronchiectasi
azithromycin
also
often
prescrib
conveni
oncedaili
dose
randomis
control
trial
involv
acut
exacerb
children
bronchiectasi
publish
knowledg
hypothesis
azithromycin
noninferior
amoxicillinclavulan
resolv
exacerb
children
bronchiectasi
parallelgroup
doubledummi
doubleblind
noninferior
randomis
control
trial
three
australian
one
new
zealand
hospit
april
august
enrol
children
age
year
radiograph
proven
bronchiectasi
unrel
cystic
fibrosi
start
exacerb
children
randomli
assign
oral
suspens
either
amoxicillinclavulan
mgkg
twice
daili
placebo
azithromycin
mgkg
per
day
placebo
day
use
permut
block
randomis
stratifi
age
site
caus
conceal
alloc
primari
outcom
resolut
exacerb
defin
return
baselin
day
perprotocol
popul
noninferior
margin
assess
sever
secondari
outcom
includ
durat
exacerb
time
next
exacerb
laboratori
respiratori
qualityoflif
measur
microbiolog
trial
regist
australiannew
zealand
registri
find
screen
children
enrol
children
exacerb
assign
treatment
amoxicillinclavulan
azithromycin
day
exacerb
resolv
azithromycin
group
versu
amoxicillinclavulan
group
risk
differ
show
noninferior
ci
exacerb
significantli
shorter
amoxicillinclavulan
group
azithromycin
group
median
day
iqr
vs
day
advers
event
attribut
trial
medic
children
azithromycin
group
versu
amoxicillinclavulan
group
rel
risk
ci
interpret
day
treatment
azithromycin
noninferior
amoxicillinclavulan
resolv
exacerb
children
nonsever
bronchiectasi
patient
penicillin
hypersensit
like
poor
adher
azithromycin
provid
anoth
option
treat
exacerb
must
balanc
risk
treatment
failur
within
margin
longer
exacerb
durat
risk
induc
macrolid
resist
bronchiectasi
chronic
pulmonari
disord
defin
dilat
bronchi
present
clinic
chronic
product
cough
despit
recognis
increasingli
nonindigen
children
adult
longer
consid
orphan
diseas
remain
neglect
condit
although
strict
definit
bronchiectasi
exacerb
gener
characteris
increas
cough
adult
increas
sputum
volum
purul
children
exacerb
caus
increas
parent
anxieti
stress
advers
affect
qualiti
life
sever
requir
hospit
admiss
neg
affect
futur
lung
function
randomis
control
trial
done
provid
evid
best
treat
exacerb
publish
involv
small
number
particip
mani
open
label
none
includ
children
although
exacerb
trigger
often
viral
infect
antibiot
commonli
use
treatment
guid
ideal
lower
airway
microbiolog
data
often
unavail
children
unabl
provid
sputum
cultur
thu
empir
antibiot
frequent
necessari
australian
new
zealand
guidelin
bronchiectasi
recommend
amoxicillinclavulan
firstlin
empir
oral
antibiot
therapi
nonsever
exacerb
children
european
guidelin
name
antibiot
refer
paper
recommend
amoxicillinclavulan
amoxicillinclavulan
activ
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
three
bacteri
pathogen
detect
often
high
densiti
lower
airway
children
bronchiectasi
howev
amoxicillinclavulan
requir
multipl
dose
per
day
caus
gastro
intestin
symptom
oral
azithromycin
attract
altern
firstlin
therapi
long
halflif
mean
taken
less
frequent
welltoler
children
disadvantag
commun
twicedaili
dose
antibiot
amoxicillinclavulan
alway
feasibl
might
result
children
exacerb
receiv
suboptim
treat
ment
risk
continu
symptom
antibiot
resist
three
randomis
control
trial
show
azithromycin
superior
amoxicillinclavulan
treat
paediatr
communityacquir
pneumonia
howev
azithromycin
still
use
set
firstlin
treatment
acut
exacerb
children
underli
bronchiectasi
therefor
test
whether
daili
oral
azithromycin
noninferior
oral
amoxicillinclavulan
resolv
exacerb
day
treatment
also
assess
effect
intervent
exacerb
durat
timetonext
respiratori
exacerb
lung
function
qualiti
life
system
inflamm
antibiot
resist
treatmentrel
advers
effect
describ
point
preval
divers
respiratori
virus
mycoplasma
pneumonia
chlamydial
spp
exacerb
parallelgroup
doubledummi
doubleblind
placebocontrol
randomis
trial
four
hospit
australia
new
zealand
april
august
studi
protocol
publish
independ
data
safeti
monitor
committe
monitor
studi
children
age
year
attend
respiratori
clinic
three
tertiari
paediatr
hospit
brisban
sydney
auckland
gener
paediatr
clinic
darwin
elig
enrol
receiv
diagnosi
bronchiectasi
respiratori
physician
base
clinic
featur
result
chest
highresolut
ct
scan
within
past
year
follow
regularli
respiratori
physician
least
two
respiratori
exacerb
previou
month
exclud
children
current
recent
sever
exacerb
bronchiectasi
dyspnoea
hypoxia
spo
air
admit
hospit
previou
week
cystic
fibrosi
liver
dysfunct
hypersensit
lactam
macrolid
antibiot
detect
pseudomona
aeruginosa
within
past
evid
studi
studi
began
search
pubm
cochran
databas
randomis
control
trial
involv
bronchiectasi
repeat
search
jan
use
term
bronchiectasi
control
trial
search
use
keyword
antibiot
bronchiectasi
exacerb
databas
search
restrict
report
english
found
six
randomis
control
trial
antibiot
treatment
exacerb
adult
one
placebocontrol
remain
five
compar
two
differ
antibiot
none
macrolid
three
openlabel
involv
small
number
patient
rang
none
children
studi
studi
longterm
use
macrolid
adult
children
bronchiectasi
publish
still
strong
data
antibiot
acut
exacerb
bronchiectasi
children
knowledg
first
randomis
control
trial
compar
amoxicillinclavulan
azithromycin
treat
exacerb
children
bronchiectasi
show
within
margin
azithromycin
noninferior
amoxicillinclavulan
resolv
symptom
day
treat
acut
exacerb
bronchiectasi
take
significantli
longer
resolv
although
azithromycin
noninferior
amoxicillinclavulan
treat
nonsever
acut
exacerb
bronchiectasi
children
exacerb
might
take
significantli
longer
resolv
risk
induc
macrolid
resist
consid
although
azithromycin
might
use
cautious
patient
penicillin
hypersensit
less
frequent
dose
might
improv
adher
amoxicillinclavulan
remain
first
choic
empir
antibiot
month
past
current
infect
nontubercul
mycobacteria
receiv
shortterm
lactam
macrolid
antibiot
within
past
week
receiv
treatment
cancer
children
take
longterm
antibiot
week
manag
bronchiectasi
exclud
mainten
antibiot
ceas
take
studi
medic
particip
hospit
human
research
ethic
committe
approv
studi
parent
primari
caregiv
gave
written
inform
consent
child
particip
studi
children
age
older
year
also
provid
written
assent
randomis
stratifi
site
brisban
darwin
sydney
auckland
age
year
year
underli
caus
either
postinfecti
idiopath
immunodefici
aspir
primari
ciliari
dyskinesia
computergener
permut
block
block
size
randomis
alloc
sequenc
ratio
prepar
statistician
studi
team
time
exacerb
child
alloc
next
number
randomis
list
maintain
local
hospit
pharmacist
except
darwin
list
maintain
brisban
pharmacist
statistician
trial
pharmacist
involv
studi
sequenc
prepar
alloc
respect
particip
caregiv
studi
coordin
variou
site
investig
mask
treatment
assign
data
analysi
complet
particip
receiv
one
activ
trial
medic
equival
volum
placebo
trial
medic
placebo
manufactur
institut
drug
technolog
australia
melbourn
vic
australia
similar
tast
colour
respect
antibiot
activ
medic
amoxicillinclavulan
azithromycin
repackag
relabel
antibiot
respect
placebo
provid
ident
opaqu
bottl
trial
medic
suppli
dri
powder
reconstitut
home
ad
equal
volum
water
placebo
activ
medic
begin
treatment
exacerb
day
children
randomli
assign
receiv
oral
suspens
either
amoxicillinclavulan
mgkg
twice
daili
placebo
azithromycin
mgkg
per
day
placebo
treatment
continu
day
unless
child
exit
studi
children
whose
exacerb
resolv
day
receiv
openlabel
oral
amoxicillinclavulan
usual
treatment
studi
drug
administ
famili
caregiv
adher
assess
return
studi
medic
bottl
children
follow
month
exacerb
next
exacerb
finish
studi
treatment
whichev
earlier
singl
exac
bation
per
enrol
child
includ
studi
deep
nasal
swab
collect
recruit
baselin
immedi
start
treatment
exacerb
day
cessat
day
place
skim
milk
trypton
glucos
glycerol
broth
transport
laboratori
storag
swab
cultur
common
respiratori
bacteria
phenotyp
antibiot
resist
test
done
establish
method
nucleic
acid
also
extract
broth
nasal
swab
collect
day
test
respiratori
virus
pneumonia
chlamydial
spp
use
realtim
pcr
assay
describ
previous
spirometri
done
baselin
begin
end
exacerb
children
abl
test
age
year
fev
predict
record
research
nurs
contact
parent
caregiv
month
telephon
email
onlin
survey
collect
data
exacerb
parent
caregiv
also
ask
contact
studi
coordin
busi
hour
oncal
physician
studi
afterhour
thought
child
exacerb
child
assess
suitabl
start
studi
medic
encourag
attend
clinic
seen
one
studi
doctor
start
studi
medic
upon
fulfil
definit
exacerb
studi
particip
remot
rural
area
unabl
attend
clinic
studi
medic
qualityoflif
questionnair
sent
child
take
trial
medic
parent
caregiv
kept
daili
cough
diari
advers
event
diari
could
contact
research
staff
suspect
advers
effect
relat
treatment
nonsever
exacerb
defin
increas
cough
frequenc
chang
charact
cough
dri
wet
increas
sputum
volum
purul
least
day
unaccompani
dyspnoea
hypoxia
spo
air
need
hospit
admiss
accord
treat
clinician
resolut
exacerb
defin
priori
cough
score
daili
symptom
diari
return
baselin
least
day
accompani
resolut
new
addit
symptom
sign
associ
episod
research
nurs
telephon
parent
caregiv
day
day
record
advers
event
clinic
review
includ
examin
symptom
diari
done
day
day
day
resolut
determin
record
baselin
state
child
determin
enrol
valid
cough
diari
card
primari
outcom
proport
children
whose
exacerb
resolv
time
within
day
treatment
children
withdrew
studi
receiv
addit
antibiot
treatment
exacerb
categoris
nonresolv
secondari
clinic
outcom
hospit
admiss
exacerb
durat
persist
symptom
return
baselin
state
time
next
exacerb
chang
forc
expiratori
volum
percent
fev
predict
parent
coughspecif
qualityoflif
score
treatmentrel
advers
event
secondari
laboratori
outcom
chang
peripher
white
blood
cell
count
creactiv
protein
crp
nasal
respiratori
bacteri
pathogen
includ
antibiot
suscept
day
day
well
respiratori
virus
atyp
pathogen
day
laboratori
outcom
avail
subset
children
children
underw
venepunctur
second
nasal
swab
taken
seriou
advers
event
defin
priori
unexpect
medic
occurr
result
death
lifethreaten
caus
signific
disabl
incapac
hospit
admiss
seriou
advers
event
report
independ
data
safeti
monitor
board
seriou
advers
event
occur
studi
period
judg
associ
trial
medic
trial
drug
ceas
base
sampl
size
noninferior
hypothesi
compar
oral
azithromycin
amoxicillinclavulan
resolut
day
true
betweengroup
differ
assum
zero
noninferior
margin
defin
absolut
differ
expect
exacerb
resolv
amoxicillinclavulan
group
size
noninferior
margin
chosen
respiratori
physician
studi
determin
view
clinic
accept
loss
efficaci
compens
azithromycin
dose
profil
potenti
increas
treatment
adher
daili
supervis
use
remot
rural
set
resolut
percentag
inform
pilot
studi
children
treat
oral
amoxicillinclavulan
nonsever
exacerb
children
symptom
resolv
day
achiev
power
onesid
would
requir
sampl
size
children
per
arm
primari
outcom
captur
randomli
assign
particip
account
attrit
sampl
size
calcul
defin
azithromycin
noninferior
amoxicillinclavulan
lower
bound
ci
risk
differ
proport
children
whose
exacerb
resolv
greater
present
summari
statist
median
iqr
continu
data
number
categor
data
also
present
normal
distribut
data
mean
sd
appendix
analys
primari
endpoint
perprotocol
popul
intentiontotreat
sensit
analys
twosid
ci
perprotocol
analysi
includ
children
receiv
studi
drug
day
protocol
deviat
could
affect
efficaci
also
includ
child
switch
intraven
antibiot
worsen
symptom
treatment
failur
compar
primari
outcom
group
use
generalis
linear
regress
model
binomi
famili
ident
link
calcul
absolut
differ
risk
resolut
analys
secondari
endpoint
children
data
avail
per
protocol
sensit
analys
done
intentiontotreat
popul
limit
analysi
bacteriolog
data
nasal
swab
particip
provid
pair
swab
day
day
median
regress
compar
median
durat
exacerb
day
timetonext
exacerb
day
two
group
children
whose
symptom
resolv
within
day
day
achiev
cure
unknown
maximum
timetoresolut
valu
intentiontotreat
popul
includ
children
randomli
assign
took
least
one
dose
studi
medic
perprotocol
popul
includ
children
complet
treatment
includ
admit
hospit
exclud
one
child
discontinu
treatment
pseudomona
aeruginosa
isol
intoler
treatment
see
onlin
appendix
obtain
cohort
assign
use
cox
proport
hazard
model
kaplanmei
surviv
analysi
compar
two
group
timetonext
exacerb
confirm
proport
hazard
assumpt
violat
use
schoenfeld
residu
visual
use
loglog
plot
also
compar
parent
coughspecif
qualityoflif
score
day
higher
valu
within
day
two
treatment
group
linear
regress
main
effect
treatment
group
score
base
line
includ
covari
base
minimum
import
score
differ
addit
apriori
sensit
analysi
primari
secondari
endpoint
particip
receiv
longterm
macrolid
time
exacerb
use
statist
packag
social
scienc
version
stata
version
analys
data
test
twotail
ci
report
appropri
statist
signific
set
p
less
statist
analysi
plan
approv
studi
investig
data
safeti
manag
committe
data
analys
data
analys
reveal
arm
child
alloc
trial
regist
australian
new
zealand
clinic
trial
registri
sponsor
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
vg
abc
mjb
rsw
access
raw
data
correspond
author
full
access
data
studi
final
respons
decis
submit
public
children
met
inclus
criteria
screen
studi
figur
parent
children
declin
particip
anoth
children
alreadi
enrol
parallel
trial
also
declin
recruit
treat
exacerb
studi
period
overal
children
exacerb
randomli
assign
either
amoxicillinclavulan
azithromycin
april
aug
recruit
continu
beyond
plan
sampl
size
centr
randomis
list
block
randomis
children
recruit
remot
rural
area
given
studi
medic
baselin
visit
start
time
next
exacerb
last
followup
visit
feb
characterist
two
group
similar
baselin
tabl
begin
exacerb
appendix
p
children
complet
week
treatment
return
empti
bottl
medic
adher
amoxicillinclavulan
group
azithromycin
group
perprotocol
popul
number
children
whose
exacerb
symptom
resolv
day
amoxicillinclavulan
group
versu
azithromycin
group
risk
differ
ci
fall
within
apriori
noninferior
margin
figur
sensit
analysi
intentiontotreat
popu
lation
exac
bation
resolv
day
children
amoxicillinclavulan
group
azithromycin
group
risk
differ
ci
median
time
resolut
exacerb
day
shorter
amoxicillinclavulan
group
azithromycin
group
perprotocol
intentiontotreat
analys
tabl
contrast
median
time
next
exacerb
similar
group
tabl
appendix
p
likelihood
exacerb
followup
similar
group
perprotocol
hazard
ratio
ci
intentiontotreat
group
ci
similarli
detect
signific
differ
group
chang
inflammatori
biomark
fev
predict
parent
coughspecif
qualityoflif
score
tabl
children
provid
pair
nasal
swab
specimen
day
day
bacteri
pathogen
cultur
h
influenza
pneumonia
catarrhali
staphylococcu
aureu
children
day
appendix
pp
bacteriolog
profil
nasal
swab
includ
carriag
azithromycinresist
organ
similar
treatment
group
start
exacerb
appendix
pp
one
child
whose
sputum
contain
pseudomona
aeruginosa
withdrew
trial
begin
antipseudomon
therapi
day
number
children
carri
pathogen
halv
patient
carri
pneumonia
day
clear
except
one
child
amoxicillinclavulan
group
children
whose
swab
contain
pathogen
day
four
amoxicillinclavulan
group
eight
ten
receiv
azithromycin
carri
intentiontotreat
popul
ci
perprotocol
popul
ci
azithromycinresist
organ
azithromycinresist
aureu
isol
treatment
group
chang
studi
appendix
pp
children
nasal
swab
taken
begin
exacerb
viru
identifi
amoxicillinclavulan
group
azithromycin
group
among
children
nasal
swab
posit
respiratori
viru
two
virus
detect
children
one
child
three
virus
present
rhinoviru
common
viru
detect
follow
parainfluenza
respiratori
syncyti
viru
human
metapneumoviru
adenoviru
influenza
b
human
enteroviru
human
bocaviru
human
polyomaviru
wu
pneumonia
c
pneumonia
identifi
one
child
overal
children
azithromycin
group
one
symptom
attribut
trial
medic
nausea
vomit
diarrhoea
rash
compar
amoxicillinclavulan
group
rel
risk
ci
children
nine
children
group
withdrew
studi
earli
start
openlabel
antibiot
vomit
repeatedli
trial
medic
rel
risk
ci
three
children
azithromycin
group
two
amoxicillinclavulan
group
admit
hospit
worsen
respiratori
symptom
trial
rel
risk
ci
tabl
children
withdrew
studi
admit
hospit
receiv
openlabel
amoxicillinclavulan
per
studi
protocol
remain
three
children
azithromycin
group
receiv
either
cotrimoxazol
azithromycin
amoxicillinclavulan
prednisolon
continu
vomit
report
children
receiv
openlabel
antibiot
without
accompani
placebo
sensit
analysi
exclud
children
take
longterm
macrolid
alter
find
appendix
pp
posthoc
subgroup
analys
base
age
vs
year
identif
viru
present
absent
begin
exacerb
shown
appendix
p
found
week
oral
azithromycin
noninferior
within
margin
week
oral
amoxicillinclavulan
resolv
symptom
children
experienc
nonsever
exacerb
bronchiectasi
howev
durat
exacerb
shorter
median
day
children
receiv
amoxicillinclavulan
azithromycin
signifi
cant
differ
group
outcom
time
next
exacerb
inflammatori
marker
fev
predict
qualityoflif
score
azithro
mycin
resist
bacteri
pathogen
common
azithromycin
group
gastro
intestin
problem
includ
nausea
diarrhoea
common
drugrel
advers
event
signific
differ
two
antibiot
although
adher
percentag
point
better
amoxicillinclavulan
group
differ
statist
signific
although
antibiot
gener
well
toler
nine
children
treatment
group
withdrew
trial
vomit
almost
half
children
respiratori
virus
detect
begin
exacerb
atyp
pathogen
rare
noninferior
margin
rel
wide
without
placebocontrol
trial
amoxicillinclavulan
azithromycin
guid
treatment
bronchiectasi
exacerb
children
noninferior
margin
base
respiratori
physician
expert
opinion
clinic
accept
loss
efficaci
compens
azithro
mycin
favour
dose
profil
trial
first
compar
antibiot
efficaci
treat
exacerb
children
bronchiectasi
past
two
decad
bronchiectasi
recognis
increasingli
rel
common
often
underdiagnos
underresearch
chronic
diseas
lower
airway
microbi
profil
children
bronchiectasi
differ
adult
disord
children
cystic
fibrosi
data
children
bronchiectasi
import
trial
also
first
compar
amoxicillinclavulan
azithromycin
use
noninferior
hypothesi
determin
priori
amoxicillinclavulan
use
refer
treatment
australia
new
zealand
recommend
firstlin
anti
biotic
outpati
manag
ment
children
bronchiec
tasi
lower
airway
specimen
unavail
abl
similarli
latest
european
adult
guidelin
refer
earlier
public
list
amoxicillinclavulan
first
option
acut
exacerb
adult
bronchiectasi
without
p
aeruginosa
infect
howev
guidelin
explicitli
recommend
amoxicillinclavulan
set
although
antibiot
underpin
treatment
bronchiectasi
exacerb
optimum
durat
treatment
dose
regimen
unknown
european
guidelin
recommend
day
therapi
state
level
evid
low
base
intraven
rather
oral
antibiot
although
week
standard
routin
clinic
practic
chose
week
antibiot
trial
basi
prior
data
prospect
cohort
studi
children
follow
childmonth
exacerb
treat
intraven
antibiot
follow
persist
symptomsi
exacerb
resolv
gener
patient
admit
hospit
week
follow
initi
oral
antibiot
resolut
occur
within
next
week
addit
pilot
work
involv
children
base
valid
diari
card
found
six
cough
free
day
nine
day
day
day
long
halflif
azithromycin
allow
conveni
dose
schedul
amoxicillinclavulan
make
attract
altern
adher
particularli
difficult
directli
supervis
therapi
feasibl
azithromycin
good
activ
pneumonia
catarrhali
atyp
pathogen
although
latter
may
import
patient
popul
least
case
azithromycin
might
effect
amoxicillinclavulan
erad
h
influenza
predomin
pathogen
lower
airway
children
bronchiectasi
use
noninferior
design
trial
sever
studi
compar
efficaci
azithromycin
amoxicillinclavulan
treat
lower
respiratori
tract
infect
children
adult
cochran
review
includ
studi
adult
three
children
compar
day
treatment
azithromycin
day
either
amoxicillin
amoxicillinclavulan
treat
lower
respiratori
infect
review
show
clinic
failur
microbi
erad
advers
event
measur
day
significantli
differ
treatment
group
howev
studi
uncertain
methodolog
qualiti
subgroup
analysi
adult
acut
bronchiti
show
clinic
failur
significantli
lower
azithromycin
group
nevertheless
none
studi
includ
patient
bronchiectasi
use
predefin
noninferior
hypothesi
limit
valid
overal
conclus
contrast
investigatorblind
ran
domis
control
trial
children
acut
otiti
media
tympanocentesi
identifi
bacteri
pathogen
report
amoxicillinclavulan
significantli
efficaci
azithromycin
produc
clinic
cure
vs
p
also
show
azithromycin
fail
erad
h
influenza
children
despit
invitro
suscept
h
influenza
strain
azithromycin
although
find
azithromycin
noninferior
amoxicillinclavulan
resolv
symptom
nonsever
bronchiectasi
exacerb
children
day
median
time
resolut
day
longer
azithromycin
group
find
taken
account
choos
antibiot
bronchiectasi
exacerb
caus
substanti
morbid
diseas
burden
includ
impair
qualiti
life
probabl
child
care
school
absente
children
work
absenc
parent
major
concern
indiscrimin
use
azithromycin
induct
macrolid
resist
risk
treatment
failur
inde
trial
almost
one
quarter
children
respiratori
bacteri
pathogen
nasal
swab
begin
exacerb
azithromycinresist
strain
find
consist
earlier
studi
presum
reflect
common
usag
macrolid
patient
commun
unlik
respiratori
pathogen
azithromycinresist
aureu
strain
might
persist
follow
cessat
antibiot
concern
especi
set
meticillinresist
aureu
alreadi
preval
indigen
children
studi
overrepres
among
patient
bronchiectasi
also
high
rate
local
invas
infect
aureu
includ
meticillinresist
aureu
increas
macrolideresist
could
therefor
complic
treatment
extra
pulmonari
infect
highrisk
popul
notwithstand
novelti
studi
sever
limit
unequ
number
patient
two
treatment
group
probabl
result
block
randomis
sitespecif
stratif
base
age
caus
lead
concurr
randomis
list
nevertheless
group
evenli
match
second
optimum
antibiot
dose
treat
bronchiectasi
exacerb
unknown
commonli
use
dose
formul
amoxicillinclavulan
avail
australia
new
zealand
mgkg
per
day
efficaci
treat
children
protract
bacteri
bronchiti
henc
pragmat
dose
chosen
studi
howev
mgkg
per
day
amoxicillin
recommend
treat
childhood
pneumonia
set
antibiot
resist
similarli
without
studi
compar
differ
dose
azithromycin
treat
lower
respiratori
tract
infect
bronchiectasi
exacerb
use
commonli
recommend
mgkg
per
day
regimen
correspond
total
weekli
dose
mgkg
use
success
trial
longterm
azithromycin
reduc
exacerb
frequenc
children
bronchiectasi
third
time
next
exacerb
base
parent
recal
symptom
although
exacerb
might
record
reason
believ
would
unevenli
distribut
treatment
group
fourth
children
requir
hospit
admiss
exacerb
randomli
assign
could
explain
favour
resolut
rate
howev
enrol
children
deem
unwel
enough
need
intraven
antibiot
oral
antibiot
trial
ethic
unaccept
last
children
unabl
expector
deep
nasal
swab
collect
describ
previous
although
specimen
reflect
poorli
lower
airway
microbiolog
know
nasopharyng
carriag
import
commun
perspect
princip
reservoir
spread
antibioticresist
bacteria
conclus
treat
children
nonsever
exacerb
bronchiectasi
found
oral
azithromycin
noninferior
within
margin
oral
amoxicillinclavulan
compromis
use
azithromycin
instead
amoxicillinclavulan
exacerb
may
last
much
day
longer
potenti
risk
induc
macrolid
resist
also
consid
azithromycin
therefor
regard
altern
treatment
bronchiectasi
exacerb
children
penicillin
hypersensit
highrisk
poor
adher
multipl
daili
dose
directli
observ
therapi
possibl
randomis
control
trial
popul
patient
bronchiectasi
need
valid
result
present
studi
data
avail
amoxicillinclavulan
remain
empir
firstlin
therapi
choic
treat
nonsever
exacerb
bronchiectasi
children
abc
conceiv
studi
abc
psm
kg
pva
kafo
pj
ibm
design
studi
vg
abc
psm
cab
gbm
hmb
pva
hp
recruit
particip
hp
gbm
collect
data
ac
randomli
assign
patient
dispens
medic
vg
coordin
studi
followup
statist
analysi
vg
abc
mjb
rsw
access
raw
data
rsw
supervis
statist
analys
vg
wrote
first
draft
articl
abc
kg
revis
articl
author
edit
articl
approv
final
version
declar
compet
interest
